Trial Profile
Pharmacotherapy of Pervasive Developmental Disorders.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jan 2019
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary)
- Indications Mental retardation; Pervasive child development disorders
- Focus Therapeutic Use
- 17 May 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 03 Jun 2014 Planned End Date changed from 1 Mar 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
- 29 Jan 2013 Planned End Date changed from 1 Mar 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.